Medicare Retail Drug Spending Accelerates In 2018 Despite Price Declines
Executive Summary
Prices for retail drugs across US payers decreased for the first time in years, driven by a drop in generic prices and “little to no growth” in prices for brands.
You may also be interested in...
Retail Drug Spending In US Flat For 2017 Due Mainly To 'Non-Price' Factors
Drop in number of prescriptions dispensed for opioids contributed to minimal spending growth for retail prescription drugs in 2017, according to latest CMS National Health Expenditures Report.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.